Home / Recalls / Teva Pharmaceuticals USA / D-0857-2018

D-0857-2018 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

Recall Details

Product Type
Drugs
Report Date
May 30, 2018
Initiation Date
April 30, 2018
Termination Date
January 14, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
30,382 patches

Product Description

Lidocaine Patch 5% (700 mg) ,(NDC 0591-3525-11), 30 envelopes containing 1 patch each/ 30 Patches/Carton (NDC 0591-3525-30)

Reason for Recall

Failed Stability Specifications

Distribution Pattern

United States

Code Information

Carton Lot Number:1147020B Patch (Envelope) Lot Number: 1147020

Other recalls by Teva Pharmaceuticals USA

  • D-0519-2026 Class II — Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 (April 24, 2026)
  • D-0521-2026 Class II — Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, ND (April 6, 2026)
  • D-0473-2026 Class II — Clonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems (March 19, 2026)
  • D-0474-2026 Class II — Clonidine Transdermal System, USP, 0.3 mg/day, supplied in cartons of 4 Systems (March 19, 2026)
  • D-0472-2026 Class II — Clonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems (March 19, 2026)
  • D-0406-2026 Class II — Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 (March 17, 2026)
  • D-0404-2026 Class II — Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 (March 17, 2026)
  • D-0405-2026 Class II — Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 (March 17, 2026)
  • D-0355-2026 Class II — Metoprolol Succinate Extended-Release Tablets, 50 mg, 100 tablets bottles (NDC: (January 29, 2026)
  • D-0357-2026 Class II — Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx O (January 29, 2026)